To combat the nation's third
deadliest cancer, the phase 1b / 2 open - label study will explore the
combination of standard chemotherapy and two immunotherapy agents: an anti-PD-1 checkpoint inhibitor and a novel antibody targeting CD40, a protein that when activated can drive the immune system to
attack tumors.